Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fulvestrant - AstraZeneca

Next Previous
Drug Profile

Fulvestrant - AstraZeneca

Alternative Names: Faslodex; ICI 182780; ZD 182780; ZD 9238; ZM 182780

Latest Information Update: 08 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Baylor Research Institute; Celcuity; Eli Lilly and Company; Novartis; Seagen
  • Class Antineoplastics; Estradiol congeners; Estrenes; Fluorinated hydrocarbons; Small molecules; Sulfoxides
  • Mechanism of Action Estrogen receptor antagonists; Selective estrogen receptor degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Precocious puberty
  • No development reported Endometrial cancer
  • Discontinued Endometriosis

Most Recent Events

  • 08 Jan 2026 Fulvestrant is still in phase-III clinical trials in Breast cancer (Combination therapy, Second-line therapy or greater, Late-stage disease, Inoperable/Unresectable, Metastatic disease) in Spain (IM) (NCT04305496)
  • 08 Jan 2026 Fulvestrant is still in phase-III clinical trials in Breast cancer (Late-stage disease, Combination therapy, Second-line therapy or greater) in USA, Argentina, Australia, Brazil, Mexico and Singapore (IV) (NCT05486143) (EudraCT2021-005235-24)
  • 08 Jan 2026 Phase III CAPItello-291 trial in Breast cancer (Combination therapy, Second-line therapy or greater, Late-stage disease, Inoperable/Unresectable, Metastatic disease) is ongoing in Argentina, Australia, Belgium, Canada, China, France, Germany, Hungary, Israel, Italy, Japan, Peru, Poland, Russia, South Korea, Taiwan, United Kingdom, USA (IM) (NCT04305496)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top